The Effect of Selenium Supplementation on Glucose Homeostasis and Lipid Profile in Women with Metabolic Syndrome

Effect of selenium supplementation on glucose homeostasis and lipid profile in women with metabolic syndrome

In this study, 70 women with metabolic syndrome referred to comprehensive health care centers in Kiar city were randomly divided into two groups: selenium and placebo

This double-blind clinical trial was conducted at the Kyar County Comprehensive Health Service Center. At first, the demographic questionnaire was filled out and the patients were asked to go to the laboratory for blood tests and then the necessary tests were taken.

Those with metabolic syndrome were chosen who had three of the following criteria to be diagnosed as metabolic syndrome: abnormal fasting blood glucose (equal to or greater than 110 mg/dl), dyslipidemia (triglyceride greater than or equal to 150 mg/dl or HDL cholesterol less than 50 mg/dl), and abdominal obesity (waist circumference in women > 88 cm), based on the indices presented in ATP III. The inclusion criteria were no consumption of antioxidant supplements, no underlying diseases including kidney diseases, hypothyroidism, digestive diseases, dyspepsia, etc., not being in menopause, not having weight loss diet over the last six months, not taking any drugs affecting the level of blood lipids, no pregnancy and breast-feeding. On the other hand, no willingness to continue the cooperation, pregnancy, not adhering to the study protocol, developing special diseases during the study were among the exclusion criteria. Note that patients taking insulin were also excluded.

In the present study, the intervention group received 200 microgram selenium capsule and the placebo group received dextrose capsule in the same form and color.

FBS , Insulin,HOMA-IR, QUICKI, TRIGLYCERID, HDL cholestrol, LDL cholestrol, total cholestrol

The subjects were categorized into selenium and placebo groups as two random block designs. In the selenium group, 200 mcg selenium capsule while in the placebo group, a placebo capsule which was identical to selenium in terms of color and appearance were given to the subjects for 8 weeks.

In this study, patients and people who will do the tests will not know if they are taking selenium or placebo, and only the researcher and data analyzer will know how to blind.

Information on major and minor consequences will be shared.

One year after publishing the documentation

Anyone working in this field can apply for documentation.

People can access the documentation via email.

People can access the documentation via email.

People can access the desired documentation in a file if they email the person in charge.